Novonesis (Novozymes) B (MEX:NSISN) ROCE %: 7.52% (As of Mar. 2026)


MEX:NSISN Novonesis (Novozymes) B MEX:NSISN
91 GF Score
Price MXN911.11
GF Value MXN979.45
! 3 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B ROCE %?

Novonesis (Novozymes) B MEX:NSISN 91 ROCE % is 7.52% as of Mar. 2026. GuruFocus rates MEX:NSISN with a GF Score™ of 91/100 and a GF Value™ of MXN979.45. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novonesis (Novozymes) B's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.52%.

Novonesis (Novozymes) B  (MEX:NSISN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novonesis (Novozymes) B ROCE % Related Terms

Novonesis (Novozymes) B ROCE % Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B ROCE % Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.27 21.93 18.31 5.98 5.75

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.93 5.99 5.23 3.23 7.52
MEX:NSISN
91GF Score
Novonesis (Novozymes) B MEX:NSISN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B ROCE % Calculation

Novonesis (Novozymes) B's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=17113.849/( ( (331848.037 - 23766.763) + (344703.735 - 57797.454) )/ 2 )
=17113.849/( (308081.274+286906.281)/ 2 )
=17113.849/297493.7775
=5.75 %

Novonesis (Novozymes) B's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=22789.996/( ( (344703.735 - 57797.454) + (344462.095 - 25483.436) )/ 2 )
=22789.996/( ( 286906.281 + 318978.659 )/ 2 )
=22789.996/302942.47
=7.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.52% mean?
Novonesis (Novozymes) B (MEX:NSISN) has a ROCE % of 7.52% as of Mar. 2026.
Is Novonesis (Novozymes) B's ROCE % too high?
Novonesis (Novozymes) B's current ROCE % is 7.52%. The Chemicals industry median ROCE % is 6.45. Novonesis (Novozymes) B's value of 7.52% is 16.7% above this industry median. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's ROCE % compare to LIN and SHW?
Novonesis (Novozymes) B's ROCE % of 7.52% can be compared against companies in the Chemicals industry. The industry median ROCE % is 6.45. Novonesis (Novozymes) B's value of 7.52% is 16.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Chemicals company?
The median ROCE % among Chemicals companies is 6.45, based on 1,594 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current ROCE % of 7.52% is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median ROCE % is 6.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current ROCE % is 7.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current ROCE % of 7.52%. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current ROCE % is 7.52% and 16.7% above the Chemicals industry median of 6.45. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current ROCE % is 7.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.

Key valuation signals for MEX:NSISN:

  • ROCE %: 7.52%
  • GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
  • GF Score™: 91/100 with 3 warning signs
  • Industry Position: 16.7% above the Chemicals median

No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score

Get the complete analysis for MEX:NSISN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN911.11
Price
MXN979.45
GF Value